The majority of what is known about PTEN and TRP53 results from KRAS-mutant lung cancer models; thus, it is critical to better understand the effects of these tumor suppressors in the context of SOX2 overexpression, which may have greater relevance to patients with LUSC. This evidence concerns the gene KRAS and lung cancer.